Artiva Biotherapeutics

Nicholas Veomett, Vice President of Corporate Development & AlloNK® Program Lead at Artiva Biotherapeutics, will be presenting at the 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗣𝗵𝗮𝗿𝗺𝗮 & 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝗶𝗻𝗴 𝗦𝘂𝗺𝗺𝗶𝘁 on November 12th at 3 PM ET in Boston. His talk, “𝙀𝙭𝙥𝙖𝙣𝙙𝙞𝙣𝙜 𝘼𝙘𝙘𝙚𝙨𝙨 𝙩𝙤 𝘾𝙚𝙡𝙡 𝙏𝙝𝙚𝙧𝙖𝙥𝙮 𝙞𝙣 𝘼𝙪𝙩𝙤𝙞𝙢𝙢𝙪𝙣𝙚 𝘿𝙞𝙨𝙚𝙖𝙨𝙚 𝙬𝙞𝙩𝙝 𝙊𝙛𝙛-𝙩𝙝𝙚-𝙎𝙝𝙚𝙡𝙛 𝘼𝙡𝙡𝙤𝙉𝙆,” will cover: • AlloNK’s use as a cryopreserved, non-genetically modified NK cell therapy, combined with monoclonal antibodies in autoimmune disease • Promising clinical data from aggressive non-Hodgkin lymphoma patients, supporting outpatient administration potential • Artiva’s robust manufacturing process, yielding over thousands of doses of AlloNK from each cord blood unit • Updates on two active clinical trials investigating AlloNK in autoimmune disease See the conference agenda here: https://lnkd.in/dixhGvwM #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #celltherapy

Artiva Biotherapeutics is pleased to welcome Alison Moore, Ph.D., to our Board of Directors. With more than 25 years of executive experience in biotech and deep cell therapy manufacturing experience, Dr. Moore will bring an important perspective as we advance our AlloNK pipeline in the clinic and work to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Read more here: https://lnkd.in/grwFkjbh  #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

Next week, our CFO & EVP, Corporate Development, Neha Krishnamohan will be at the 𝗖𝗲𝗹𝗹 𝗮𝗻𝗱 𝗚𝗲𝗻𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝘀𝗮 next week presenting on the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease. See the agenda here: https://lnkd.in/eiUpMy4 #CGMesa24 #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

We were honored to present at the 𝗖𝗮𝗻𝘁𝗼𝗿 𝟮𝟬𝟮𝟰 𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in New York last week and discuss how allogeneic NK cell therapies can transform the treatment of autoimmune diseases. 📺 If you missed it, watch the webcast here: https://lnkd.in/gnjFAMS2 #CantorHCC #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #biotech #InvestorEvent

Our CEO Fred Aslan will be presenting at the 𝗖𝗮𝗻𝘁𝗼𝗿 𝟮𝟬𝟮𝟰 𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲. Join for a Fireside Chat on 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝟴𝘁𝗵 𝗮𝘁 𝟴:𝟬𝟬 𝗔𝗠 𝗘𝗗𝗧 to learn more about the opportunity for allogeneic NK cell therapies to transform the treatment of autoimmune diseases. 🗓️ Read the press release for more details: https://lnkd.in/gvbAWyDx 🌐 Watch the webcast here: https://lnkd.in/gDkVQxAJ #CantorHCC #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #biotech #InvestorEvent

Artiva Biotherapeutics announces strong Q2 2024 financial results and recent business milestones. We’re excited to share our progress in Q2 2024, marked by important achievements: 🔹 Successfully completed an upsized $179.0 million IPO, strengthening our balance sheet 🔹 Initiated treatment for the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications 🔹 Treated the first patient in our Phase 1/1b trial targeting class III/IV lupus nephritis (LN) and expanded the trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement At Artiva, we remain committed to advancing innovative NK cell therapies for patients with serious unmet medical needs. Read the full release here: https://lnkd.in/gxskVSPd #biotech #biopharma #healthcareinnovation #ArtivaBiotherapeutics #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer

Our CEO Fred Aslan spoke with Brian Orelli, PhD, of BiotechTV about our recent #IPO, the potential of NK cell therapy to achieve deep B cell depletion to treat autoimmune disease, and how Artiva’s platform can make these cell therapies broadly accessible to patients who need them. Watch below or check out the interview here: https://lnkd.in/gFpZ5DNX #biotech #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer

Thank you to Nasdaq for celebrating our very first trade as $ARTV on July 19th. And big thanks to our team, partners, investors, and supporters for helping us achieve this important milestone! We are energized and deeply committed to making cell therapies broadly accessible to patients with autoimmune disease and cancer.  #biotech #IPO #AlloNK #lupus #NKcell #NKcelltherapy #autoimmunedisease #cancer #NasdaqListed

We are pleased to announce the pricing of an upsized $167.0 million initial public offering on the Nasdaq exchange. Read the release here: https://lnkd.in/gcTfTMJt #biotech #IPO #AlloNK #lupus #NKcell #NKcelltherapy #autoimmunedisease

“Move over CAR-T: the potential of NK cells in cell therapy” On this pharmaphorum podcast, Artiva’s CEO, Dr. Fred Aslan, talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process. Listen to the podcast on pharmaphorum’s website, which has a podcast player or the option to download the episode. It also has links to find the podcast on iTunes, Spotify, and Stitcher. https://lnkd.in/gc6vDjRf #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity #celltherapy